BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31873931)

  • 1. Hypofractionated Radiation Therapy for Unresectable/Locally Recurrent Intrahepatic Cholangiocarcinoma.
    Smart AC; Goyal L; Horick N; Petkovska N; Zhu AX; Ferrone CR; Tanabe KK; Allen JN; Drapek LC; Qadan M; Murphy JE; Eyler CE; Ryan DP; Hong TS; Wo JY
    Ann Surg Oncol; 2020 Apr; 27(4):1122-1129. PubMed ID: 31873931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
    Hong TS; Wo JY; Yeap BY; Ben-Josef E; McDonnell EI; Blaszkowsky LS; Kwak EL; Allen JN; Clark JW; Goyal L; Murphy JE; Javle MM; Wolfgang JA; Drapek LC; Arellano RS; Mamon HJ; Mullen JT; Yoon SS; Tanabe KK; Ferrone CR; Ryan DP; DeLaney TF; Crane CH; Zhu AX
    J Clin Oncol; 2016 Feb; 34(5):460-8. PubMed ID: 26668346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcomes and toxicity of proton beam therapy for advanced cholangiocarcinoma.
    Makita C; Nakamura T; Takada A; Takayama K; Suzuki M; Ishikawa Y; Azami Y; Kato T; Tsukiyama I; Kikuchi Y; Hareyama M; Murakami M; Fuwa N; Hata M; Inoue T
    Radiat Oncol; 2014 Jan; 9():26. PubMed ID: 24422711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Limitations of conventional doses of chemoradiation for unresectable biliary cancer.
    Crane CH; Macdonald KO; Vauthey JN; Yehuda P; Brown T; Curley S; Wong A; Delclos M; Charnsangavej C; Janjan NA
    Int J Radiat Oncol Biol Phys; 2002 Jul; 53(4):969-74. PubMed ID: 12095564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies.
    Yeung R; Bowen SR; Chapman TR; MacLennan GT; Apisarnthanarax S
    Pract Radiat Oncol; 2018; 8(4):287-293. PubMed ID: 29452863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proton beam therapy for unresectable intrahepatic cholangiocarcinoma.
    Ohkawa A; Mizumoto M; Ishikawa H; Abei M; Fukuda K; Hashimoto T; Sakae T; Tsuboi K; Okumura T; Sakurai H
    J Gastroenterol Hepatol; 2015 May; 30(5):957-63. PubMed ID: 25376272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated Radiation Therapy: A Potential Option for Advanced Intrahepatic Cholangiocarcinoma.
    Shindoh J
    Ann Surg Oncol; 2020 Apr; 27(4):983-984. PubMed ID: 31848809
    [No Abstract]   [Full Text] [Related]  

  • 8. Stereotactic body radiotherapy (SBRT) for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    Gkika E; Hallauer L; Kirste S; Adebahr S; Bartl N; Neeff HP; Fritsch R; Brass V; Nestle U; Grosu AL; Brunner TB
    BMC Cancer; 2017 Nov; 17(1):781. PubMed ID: 29162055
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis.
    Tao R; Krishnan S; Bhosale PR; Javle MM; Aloia TA; Shroff RT; Kaseb AO; Bishop AJ; Swanick CW; Koay EJ; Thames HD; Hong TS; Das P; Crane CH
    J Clin Oncol; 2016 Jan; 34(3):219-26. PubMed ID: 26503201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.
    Parzen JS; Hartsell W; Chang J; Apisarnthanarax S; Molitoris J; Durci M; Tsai H; Urbanic J; Ashman J; Vargas C; Stevens C; Kabolizadeh P
    Radiat Oncol; 2020 Nov; 15(1):255. PubMed ID: 33148296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study.
    Bisello S; Buwenge M; Palloni A; Autorino R; Cellini F; Macchia G; Deodato F; Cilla S; Brandi G; Tagliaferri L; Cammelli S; Valentini V; Morganti AG; Mattiucci GC
    Anticancer Res; 2019 Jun; 39(6):3095-3100. PubMed ID: 31177154
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of Patients With Unresectable Cholangiocarcinoma Treated With Proton Beam Therapy.
    Hung SP; Huang BS; Hsieh CE; Lee CH; Tsang NM; Chang JT; Chen JS; Chou WC; Tseng JH; Hong JH
    Am J Clin Oncol; 2020 Mar; 43(3):180-186. PubMed ID: 31764017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma.
    Elganainy D; Holliday EB; Taniguchi CM; Smith GL; Shroff R; Javle M; Raghav K; Kaseb A; Aloia TA; Vauthey JN; Tzeng CD; Herman JM; Koong AC; Krishnan SX; Minsky BD; Crane CH; Das P; Koay EJ
    Cancer Med; 2018 Oct; 7(10):4880-4892. PubMed ID: 30152073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes of previously untreated patients with unresectable intrahepatic cholangiocarcinoma following proton beam therapy.
    Shimizu S; Okumura T; Oshiro Y; Fukumitsu N; Fukuda K; Ishige K; Hasegawa N; Numajiri H; Murofushi K; Ohnishi K; Mizumoto M; Nonaka T; Ishikawa H; Sakurai H
    Radiat Oncol; 2019 Dec; 14(1):241. PubMed ID: 31881895
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome after liver resection for primary and recurrent intrahepatic cholangiocarcinoma.
    Nickkholgh A; Ghamarnejad O; Khajeh E; Tinoush P; Bruckner T; Kulu Y; Mieth M; Goeppert B; Roessler S; Weiss KH; Hoffmann K; Büchler MW; Mehrabi A
    BJS Open; 2019 Dec; 3(6):793-801. PubMed ID: 31832586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    Franzese C; Bonu ML; Comito T; Clerici E; Loi M; Navarria P; Franceschini D; Pressiani T; Rimassa L; Scorsetti M
    J Cancer Res Clin Oncol; 2020 Sep; 146(9):2289-2297. PubMed ID: 32524292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation therapy is associated with improved survival in the adjuvant and definitive treatment of intrahepatic cholangiocarcinoma.
    Shinohara ET; Mitra N; Guo M; Metz JM
    Int J Radiat Oncol Biol Phys; 2008 Dec; 72(5):1495-501. PubMed ID: 18472359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stereotactic body radiotherapy dose and its impact on local control and overall survival of patients for locally advanced intrahepatic and extrahepatic cholangiocarcinoma.
    Brunner TB; Blanck O; Lewitzki V; Abbasi-Senger N; Momm F; Riesterer O; Duma MN; Wachter S; Baus W; Gerum S; Guckenberger M; Gkika E
    Radiother Oncol; 2019 Mar; 132():42-47. PubMed ID: 30825968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and
    Manceau V; Palard X; Rolland Y; Pracht M; Le Sourd S; Laffont S; Boudjema K; Lievre A; Mesbah H; Haumont LA; Lenoir L; Brun V; Uguen T; Edeline J; Garin E
    Eur J Nucl Med Mol Imaging; 2018 Sep; 45(10):1731-1741. PubMed ID: 29560519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial hepatic yttrium-90 radioembolization in patients with unresectable intrahepatic cholangiocarcinoma: factors associated with prolonged survival.
    Hoffmann RT; Paprottka PM; Schön A; Bamberg F; Haug A; Dürr EM; Rauch B; Trumm CT; Jakobs TF; Helmberger TK; Reiser MF; Kolligs FT
    Cardiovasc Intervent Radiol; 2012 Feb; 35(1):105-16. PubMed ID: 21431970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.